| - Industry | - Sector | Dr. David Dean Halbert M.D. CEO | XDUS Exchange | - ISIN |
| United States Country | 1,769 Employees | - Last Dividend | - Last Split | - IPO Date |
Caris Life Sciences is a pioneering AI-driven precision medicine company dedicated to transforming the healthcare landscape through meticulous molecular profiling and sophisticated machine learning techniques. Specializing in the in-depth analysis of cancer at the molecular level, Caris employs advanced methods such as whole exome and whole transcriptome sequencing using patient tissue and blood samples. The company's innovative approach has enabled it to cultivate one of the world's largest multimodal clinico-genomic databases, which integrates genomic, transcriptomic, and proteomic data along with clinical outcomes, encompassing over 740,000 matched patient records.
Founded in 2008 and headquartered in Irving, Texas, Caris Life Sciences operates on an international scale, with offices in prominent medical and research hubs. The company's commitment to precision medicine is evident in its array of solutions that empower oncologists and patients, providing essential molecular information that supports therapy selection, enhances drug development, and fosters early disease detection.